JP5527690B2 - Immunoregulatory function inducer and food composition - Google Patents

Description

  The present invention relates to Lactococcus lactic acid bacteria suitable for the treatment of inflammatory diseases, in particular inflammatory bowel diseases, and / or processed products thereof, and immunoregulatory function inducers comprising the same as active ingredients, particularly from immunocompetent cells in the intestinal tract. The present invention relates to an immunoregulatory function inducer for inducing production of interleukin-10 (hereinafter, IL-10) and enhancing the immunoregulatory function. The present invention also relates to a food composition containing this as an active ingredient.

  Inflammatory bowel disease is caused by causing chronic inflammation or ulceration in the large intestine and / or small intestinal wall mucosa, and a wide variety of treatments have been developed for this type of inflammatory bowel disease. ing.

  For example, steroids and non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as drug therapy. However, this type of drug therapy has problems with long-term administration because there are problems such as side effects depending on each drug used.

  On the other hand, as a therapy without problems such as side effects, therapeutic agents for inflammatory bowel diseases, such as lactic acid bacteria and dietary fiber, mainly for improving the intestinal environment have been devised and developed. The effects of these therapeutic agents are not always sufficient, and the treatment period may be long. However, there are few physical burdens on patients, and expectations are high for their development.

  In order to meet the above demand, research on coping therapy using lactic acid bacteria has attracted attention. For example, many anti-inflammatory effects in the intestinal tract by lactic acid bacteria have been reported in animal models (Non-Patent Documents 1 to 3). However, although the effects on humans have been reported to extend the remission period in ulcerative colitis (Non-patent Document 4) and prevent the onset of ileal cystitis (Non-patent Document 5), the effects in the active period have been reported. The current situation is that it is not a definitive therapeutic agent for inflammatory bowel disease. Moreover, many of these use live bacteria, and the main mechanism of action is to improve the intestinal environment including the elimination of bacteria that exacerbate enteritis.

  Furthermore, as a new trial, Lactococcus, which produces IL-10, an anti-inflammatory cytokine by genetic manipulation, is orally administered to mice, thereby confirming an anti-inflammatory effect via IL-10 production in the large intestine. (Non-Patent Document 6). However, the IL-10 drug delivery system to the intestinal tract using this kind of genetically modified bacteria is considered difficult at present from the viewpoint of using the genetically modified bacteria to humans.

In addition to the above documents, methods for preventing and treating inflammatory bowel disease mainly composed of lactic acid bacteria have been proposed. For example, a lactobacillus lactic acid bacterium or a microbial cell-derived polysaccharide fraction is used as an active ingredient as an inflammatory bowel disease preventive or therapeutic agent, and an IL-6 production inhibitor containing this as an active ingredient, IL containing this as an active ingredient A -6 / STAT3 phosphorylation response inhibitor is known (Patent Document 1). Also, probiotic Lactobacillus salivarius strains AH102, AH103, AH105, AH109, or AH110 or variants or variants thereof may have an inflammatory activity, particularly an undesirable gastrointestinal tract such as inflammatory bowel disease or irritable bowel syndrome It is known to be useful in the prevention and / or treatment of inflammation (Patent Document 2). Furthermore, as an agent for the prevention and treatment of inflammatory bowel disease and irritable bowel syndrome, Lactobacillus gasseri, especially LG2055 cells or fermentation products thereof as active ingredients, inflammation such as ulcerative colitis, Crohn's disease, Behcet's disease, etc. It is known to prevent or treat progression of irritable bowel disease and irritable bowel syndrome, and cope with remission (Patent Document 3). It is also known to impart an immunoregulatory function using Lactococcus lactic acid cocci that induce IL-10 production or a component derived from the lactic acid cocci (Patent Document 4).
JP 2003-73285 A JP 2005-506063 A JP 2003-95963 A JP 2005-154387 A M. Schultz, etc. (Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB., Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice., Inflamm Bowel Dis ., 8 (2), pp. 71-80 (2002)) M. Schultz, etc. (Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Gottl C, Dunger N, Grunwald N, Scholmerich J, Rath HC, Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two differentiated murine models of colitis., Clin Diagno Lab Immunol, 11 (2), pp. 372-378 (2004)). M buoy area, etc. (Herias MV, Koninkx JF, Vos JG, Huis in't Veld JH, van Dijk JE., Probiotic effects of Lactobacillus casei DS in c (2), pp, 143-155 (2005)) H. Ishikawa, etc. (Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T, Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis., J Am Coll Nutr, 22 (1), pp 56-63 (2003)) P. John Chez Tsu tea, etc. (Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M., Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo -Controlled trial., Gastroenterology., 119 (2), pp. 305-309 (2000)) L. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remut E ce ter cu, t. pp. 1352-1355 (2000))

  Many of the lactic acid bacteria preparations currently used in humans are selected based on so-called probiotic characteristics such as gastrointestinal transit and colonization, and are selected in consideration of anti-inflammatory effects. There was nothing that was done. From this point, the present inventors can select a better lactic acid strain by using IL-10 production-inducing activity as an index, and thereby a strain having a high anti-inflammatory effect against inflammatory bowel disease can be selected. We found that there is a possibility of obtaining. In addition, since strains selected on the basis of so-called probiotic characteristics are used in live bacteria, there is a possibility that restrictions on quality and activity retention and usage may be required. As described in detail later, the present invention However, since dead cells can be used, the handling is easy and at the same time, there is little risk of greatly changing the intestinal environment.

  In the present invention, in order to solve these problems, a strain that induces IL-10 production in immunocompetent cells in the intestinal tract was found out of lactic acid bacteria that are food microorganisms, thereby completing the present invention. That is, the present inventors have found that Lactococcus lactic acid bacteria and / or processed products thereof, in particular, Lactococcus lactis OLS3301, (Lactococcus lactis OLS3301) or L. lactis OLS3301 strain induces IL-10 production, We have found that it is possible to enhance the regulatory function and have completed the present invention. According to the present invention, IL-10 induced by Lactococcus lactic acid bacteria of the present invention not only suppresses intestinal inflammation but also increases the number of cells responsible for immune tolerance through induction of IL-10 production. It is also expected.

  In other words, the living body originally prevents allergic reactions and inflammatory reactions by exerting immune tolerance against food and intestinal symbiotic bacteria. One of the causes of inflammatory bowel disease, which is an intractable disease, is that the immune response against intestinal bacteria that should originally live with the human body is excessive, causing continuous inflammation. As coping therapy for such diseases, it is important to restore the normal function of the living body and suppress excessive inflammation. In this regard, the present inventors have found that continuous inflammation in the intestinal tract can be alleviated / suppressed by the Lactococcus lactic acid bacteria of the present invention. It was also found that the Lactococcus lactic acid bacterium of the present invention has an inhibitory effect on the reduction of the skin barrier function due to the enhancement of the immunoregulatory function, and therefore suppresses inflammation in the skin.

  That is, the present invention mainly relates to Lactococcus lactis OLS3301 (Lactococcus lactis OLS3301) strain and other Lactococcus lactic acid bacteria and / or processed products thereof, immunoregulatory function inducers comprising the same, and A food composition comprising an effective amount is provided. This Lactococcus lactic acid bacterium and / or processed product thereof, immunoregulatory function inducer, or food composition according to the present invention has the ability to cause immunocompetent cells to produce a large amount of IL-10, an anti-inflammatory cytokine. . Therefore, in the present invention, for example, by ingesting the Lactococcus lactis OLS3301 strain, it is possible to induce IL-10 production in the immunocompetent cells of the intestinal tract and suppress inflammation. In addition, IL-10 is known to induce cell groups responsible for immune tolerance in Peyer's patches etc., and can suppress persistent inflammation due to excessive inflammatory response to enteric bacteria such as inflammatory bowel disease There is sex. In addition, the present invention is highly safe in that a lactococcus lactic acid bacterium derived from fermented food is used. And since it is a heat-killed microbial cell, quality maintenance is easy. From these facts, it can be taken orally on a daily basis and is considered to be particularly effective for diseases that require long-term administration such as inflammatory bowel disease.

  One embodiment of the present invention is a Lactococcus lactic acid bacterium that induces production of interleukin-10 (IL-10) from immunocompetent cells in the intestinal tract and enhances an immunoregulatory function and / or a processed product thereof.

  The Lactococcus lactic acid bacterium and / or the processed product thereof is a Lactococcus lactis lactic acid bacterium, and is particularly preferably a Lactococcus lactis OLS3301 strain.

  Moreover, in this invention, the Lactococcus genus lactic acid bacteria which are dead cells, and / or its processed material are preferable.

  In another aspect of the present invention, an Lactococcus lactic acid bacterium that induces production of interleukin-10 (IL-10) from immunocompetent cells in the intestinal tract and enhances an immunoregulatory function and / or a processed product thereof is used as an active ingredient. It is an immunoregulatory function inducer.

  In the immunoregulatory function inducer according to the present invention, the Lactococcus lactic acid bacterium is preferably a Lactococcus lactis species lactic acid bacterium, particularly a Lactococcus lactis OLS3301 strain.

  Furthermore, the Lactococcus lactic acid bacteria are preferably dead cells.

  Yet another aspect of the present invention provides an effective amount of Lactococcus lactic acid bacteria and / or processed products thereof that induces the production of interleukin-10 (IL-10) from immunocompetent cells in the intestinal tract and enhances the immunoregulatory function. A food composition comprising.

  The food composition according to the present invention preferably comprises an effective amount of Lactococcus lactic acid bacteria which are Lactococcus lactis strains and / or processed products thereof.

  Furthermore, the food composition according to the present invention preferably comprises an effective amount of Lactococcus lactis lactic acid bacteria, in particular, Lactococcus lactis OLS3301 (Lactococcus lactis OLS3301) strain and / or a processed product thereof.

  Furthermore, it is preferable that the Lactococcus lactic acid bacteria and / or the processed product thereof are dead cells.

  The Lactococcus lactic acid bacterium according to the present invention and / or a processed product thereof, an immunoregulatory function inducer, or a food composition has an ability of causing immunocompetent cells to produce a large amount of IL-10, which is an anti-inflammatory cytokine. For example, when taken orally, IL-10 production is induced in immunocompetent cells of the intestinal tract and exerts an inflammation-suppressing action, and induction of immune tolerance can be expected along with the ability to induce IL-10 production. Furthermore, because it is derived from fermented foods, it is safe and can be taken orally on a daily basis, and it is easy to maintain quality in the case of dead cells, so long-term use such as inflammatory bowel disease is required. It is particularly effective for diseases. Furthermore, inflammation in the skin can also be suppressed.

The graph which shows the result of the IL-10 production induction test of each strain in Example 1 by the IL-10 density | concentration (pg / ml) in the culture supernatant 24 hours after culture | cultivation. MEP194701 to MEP194753 are Lactococcus strains, MEP194754 to MEP194764 are Lactobacillus plantarum strains (L. plantarum), MEP194765 to MEP194769 are Lactobacillus species Bulgaricus species (L. bulgaricus), Thermophilus spp. (S. thermophilus), MEP194776 to MEP194777 are other strains including Bifidobacterium strains. *: A strain having strong IL-10 production-inducing activity. Colon length in the first group (negative control group, n = 7), second group (3% DSS control group, n = 6), and third group (3% DSS + OLS3301 group, n = 7) in Example 3 The average value ± standard deviation of the length (Colon length (mm)) is shown. Disease activity index in the first group (negative control group, n = 7), the second group (3% DSS control group, n = 6), and the third group (3% DSS + OLS3301 group, n = 7) in Example 3 Average value of (DAI) ± standard deviation is shown. The average value +/- standard deviation of the time-dependent change (g / hr * m < ² >) of the transepidermal water evaporation (TEWL) of each group before and behind UVB irradiation in Example 4 is shown. *: P <0.05 (Dunnett's test, 1 group (UV-B irradiation + distilled water) vs. 3 group (UV-B irradiation + Lactococcus lactis OLS3301)).

  Hereinafter, the present invention will be described in detail, but the present invention is not limited to the individual forms described below.

  In the present invention, the term “Lactococcus lactic acid bacteria” means non-spore-forming gram-positive cocci classified in the Lactobacillus Streptococcus family Lactococcus.

  Examples of Lactococcus lactic acid bacteria used in the present invention include Lactococcus lactis, Lactococcus lactis subspice cremoris, Lactococcus lactis subspice horconia b. Hordoniae), Lactococcus lactis subsp. Lactis, Lactococcus lactis subsp. Lactis biovariety lactis subsp. can be mentioned. A strain that can be particularly preferably used is the Lactococcus lactis OLS3301 strain.

  About these, it can use individually or in combination of 2 or more.

  Lactococcus lactis OLS3301 used in the present invention was deposited under the following conditions.

(1) Consigned institution name: National Institute of Technology and Evaluation, Patent Microorganism Depositary Center (2) Contact: 2-5-8 Kazusa Kamashi, Kisarazu City, Chiba Prefecture 292-0818
Phone number 0438-20-5580
(3) Accession number: NITE BP-432
(4) Display for identification: Lactococcus lactis OLS3301
(5) Original deposit date: October 4, 2007 (2007)
(6) Date of transfer to deposit under the Budapest Treaty: September 19, 2008 (2008)
Lactococcus lactis OLS3301 of the present invention has the following mycological properties.

  Lactococcus lactis OLS3301 is a Gram-positive cocci isolated from fermented milk, and has a homolactic fermentation format and growth in aerobic conditions. When this bacterium is applied on a MRS agar plate (Nissui Pharmaceutical Co., Ltd.) and cultured at 37 ° C for 48 hours in anaerobic condition using AnaeroPack Kenki (Mitsubishi Gas Chemical), round, white, smooth type, flat colony Form. The bacterial species was identified by 16S rDNA base sequence and database search. The official scientific name is Lactococcus lactis subsp. Lactis.

  IL-10 production inducing ability of Lactococcus lactic acid bacteria of the present invention is examined in vitro using mouse bone marrow-derived dendritic cells as described in, for example, JP-A-2005-154387 (Patent Document 4). And the method is also described in detail in Example 1 herein. Specifically, dendritic cells are prepared from mouse bone marrow by an appropriate method, and the obtained dendritic cells are seeded on a plate together with dead cells of Lactococcus lactic acid bacteria. After culturing in an appropriate medium such as RPMI 1640 supplemented with 10% FCS for about 24 hours, the concentration of IL-10 in the culture supernatant is measured by ELISA. The measurement of IL-10 using the ELISA method can be performed using, for example, a measurement kit commercially available from BD Bioscience.

  The immunoregulatory function promoting activity of Lactococcus lactic acid bacteria of the present invention can be examined by the colitis suppression test described in Example 3 below, the skin barrier function test described in Example 4, and the like.

  The Lactococcus lactic acid bacterium of the present invention may be either a living cell or a dead cell. Moreover, even if the Lactococcus lactic acid bacterium of this invention is a processed material, the effect of this invention is exhibited. For example, a culture of Lactococcus lactic acid bacteria, a concentrate thereof, a pasted product processed into a paste, a spray dried product, a freeze dried product, a vacuum dried product, a drum dried product, a liquid material dispersed in a medium, a diluent Diluted diluted products, crushed products obtained by crushing dried products with a mill, etc. can be used as processed products. The treatment process may be performed alone or in combination. At this time, the processed product of Lactococcus lactic acid bacteria of the present invention may contain any of live cells, dead cells, and culture supernatant. Preferably, microbial cells, more preferably dead microbial cells are contained as active ingredients. The dead cells can be prepared by one or a combination of commonly used sterilization or sterilization treatments such as heat treatment, heat and pressure treatment, radiation treatment, freeze-thaw treatment, crushing treatment, and ultrasonic treatment.

The dosage of the immunoregulatory function inducer comprising the Lactococcus lactic acid bacterium of the present invention and / or its processed product as an active ingredient depends on various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans. It can be set as appropriate in consideration. Although this invention is not limited to this, Preferably it is appropriate to administer 0.4-4000 mg / kg / day as an active ingredient, More preferably, 4.0-400 mg / kg / day is appropriate. Alternatively, it is preferable to administer 5 × 10 ^{3 to} 5 × 10 ⁷ cfu / kg / day, more preferably 5 × 10 ^{4 to} 5 × 10 ⁶ cfu / kg / day as an active ingredient. However, when ingested for the purpose of prevention and / or treatment over a long period of time, the amount may be smaller than the above range, and since this active ingredient has no safety problem, Can be used in large quantities.

  The immunoregulatory function inducer comprising the Lactococcus lactic acid bacterium of the present invention and / or a processed product thereof as an active ingredient is administered orally or parenterally (administration via suppository, gastric fistula (tube, catheter, etc.), Any of tube administration etc. can be administered.

  Examples of the dosage form of the immunoregulatory function inducer according to the present invention include oral administration such as tablets, coated tablets, capsules, granules, powders, solutions, syrups, and emulsions. These various preparations are prepared in accordance with conventional methods, in addition to the fungus body and / or processed product of the present invention, excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, and solubilizing aids. , Suspensions, coating agents and the like can be formulated using known adjuvants that can be generally used in the pharmaceutical formulation technical field.

  The food composition of the present invention comprises an effective amount of Lactococcus lactic acid bacteria and / or processed products thereof that induce IL-10 production from immunocompetent cells in the intestinal tract and enhance immunoregulatory functions.

  The food composition of the present invention can also be applied to health functional foods and foods for the sick. The health functional food system was established not only for regular foods but also for foods in the form of tablets, capsules, etc., based on domestic and foreign trends and consistency with the conventional food system for specified health use. It consists of two types of food for specified health use (individual permission type) and functional food for nutrition (standard type). It is possible to prevent and / or treat various infections by directly ingesting the Lactococcus lactic acid bacteria of the present invention and / or processed products thereof as special-purpose foods such as foods for specified health use or nutritional functional foods containing them. Become.

  When used as a food composition, specifically, various foods and drinks (milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, food for the sick Lactococcus lactic acid bacteria and / or Lactococcus lactic acid bacteria-treated products may be added to foods such as infant milk powder, foods such as lactating milk powder, and nutritional foods. The active ingredient can be used as it is, or can be used in accordance with conventional methods in ordinary food compositions such as mixing with other foods or food ingredients. Moreover, about the property, the state of the food / beverage products normally used, for example, any of solid (powder, granule, etc.), paste, liquid or suspension may be sufficient.

  Other ingredients are not particularly limited, but the food composition containing the Lactococcus lactic acid bacterium of the present invention and / or a processed product thereof includes water, protein, carbohydrate, lipid, vitamins, minerals, organic acids, Organic bases, fruit juices, flavors and the like can be used as main components. Examples of the protein include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin , Α-lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and vegetable proteins, hydrolysates thereof, butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components. Examples of the saccharide include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Examples of the lipid include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. And minerals include, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, and whey minerals. Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid. These components can be used in combination of two or more, and synthetic products and / or foods containing a large amount thereof may be used.

  The amount of Lactococcus lactic acid bacteria and / or processed product thereof of the present invention can be arbitrarily determined according to the purpose and application (immunomodulatory function inducer, food composition). Although this invention is not limited to this, The content is 0.02 to 100% (w / w) normally with respect to the whole quantity, Especially 0.2 to 100% is preferable.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited by these.

[Example 1] IL-10 production induction test of heat-killed cells, including microorganisms belonging to the genus Lactobacillus (plantarum species, Bulgaricus species), Bifidobacterium genus, Lactococcus genus, Streptococcus genus (thermophilus species) A total of 77 strains (MEP194701 to MEP194777) held by Meiji Dairies Co., Ltd. were selected as test strains, and from these heat-killed cells, selection of strains that strongly induce IL-10 production in mouse bone marrow-derived dendritic cells in vitro Was performed based on the method described in JP-A-2005-154387 (Patent Document 4).

(1) Preparation of test strain heated dead cells Each of the above-mentioned 77 strains was cultured overnight in an MRS medium according to a conventional method, collected, then washed twice with physiological saline, and further washed once with distilled water. Thereafter, the cells were killed by heating at 70 ° C. for 30 minutes.

(2) Preparation of bone marrow-derived dendritic cells Bone marrow cells of BALB / c mice (8 weeks old, female) were collected and undifferentiated cells (B220, B), using a magnetic cell separator autoMACS (Miltenyi Biotech). IAd, CD8, or CD4 antigen was negative). Further, the obtained undifferentiated cells were added to 10% FCS (fetal bovine serum) -containing RPMI1640 medium (10% FCS, 100 units / ml Penicillin, 100 μg / ml Streptoly Streptomlinto) supplemented with GM-CSF (Granulocyte Macrophage colony-stimulating Factor). , 55 nM 2-Mercaptoethanol) and then cultured for 8 days under 5% CO ₂ conditions to differentiate into dendritic cells. Further, floating cells were collected on the 8th day of culture to obtain dendritic cells.

(3) IL-10 production induction test of test strain heated dead cells The dendritic cells obtained in (2) were heated to 1 × 10 ⁵ cells / well and (1) in a 96-well flat bottom plate (Corning). Dead cells were applied at 5 × 10 ⁶ cells / well (dendritic cells: test strain = 1: 50), RPMI 1640 medium containing 10% FCS (10% FCS, 100 units / ml Penicillin, 100 μg / ml Streptomycin, 55 nM 2 -Including Mercaptoethanol) for 24 hours. The concentration of IL-10 in the culture supernatant after 24 hours of culture was measured using ELISA (solid phase enzyme immunoassay). The measurement of IL-10 was carried out using an OptEIA mouse IL-10 measurement kit (manufactured by BD Biosciences) according to the operating procedure.

(4) Results FIG. 1 shows the results of the IL-10 production induction test in terms of the IL-10 concentration (pg / ml) in the culture supernatant after 24 hours of culture. In FIG. 1, the strains marked with * indicate those having an IL-10 concentration of 1500 pg / ml or more under the experimental conditions of Example 1. As a result of the IL-10 production induction test, several strains having strong IL-10 production induction activity were selected from 77 test strains. Furthermore, Lactococcus lactis OLS3301 (hereinafter also referred to as L. lactis OLS3301) was selected from among them due to its proliferative properties.

Proliferation: Evaluation was performed using growth in an MRS medium (Lactobacilli MRS Broth, Difco, Ref. No. 288130) as an index. Culturing was started at a cell concentration of about 1 × 10 ⁷ cfu / ml and cultured at 30 ° C. for 30 hours. lactis OLS3301 had a cell concentration of 9.7 × 10 ⁸ cfu / ml after completion of the culture. In contrast, the other strains with high IL-10 production-inducing activity had a bacterial cell concentration of 0.2 to 6.0 × 10 ⁸ cfu / ml after completion of the culture.

Example 2 lactis OLS3301 Concentrated Bacteria Production Test In order to industrially produce lactic acid bacteria, it is necessary to produce the concentrated microbial cells. L. selected in Example 1. Lactis OLS3301 was tested to make it possible to produce concentrated cells. Specifically, the evaluation was carried out using growth and freezing tolerance of concentrated cells in a whey decomposition medium (pH 5.9) containing 10% whey protease degradation product, 4% glucose, and 0.5% yeast extract as an index. . When the culture was started at a cell concentration of about 1 × 10 ⁷ cfu / ml and neutralized for 10 hours at a culture temperature of 30 ° C., it proliferated well, and after 8 hours from the start of culture, the cell concentration was about 1 × 10 ¹⁰ cfu / ml was reached. Furthermore, the obtained culture broth was centrifuged and concentrated 25 times to prepare concentrated bacterial cells, which were then frozen with liquid nitrogen. Concentrated cells after freezing and thawing which were subjected to a viable cell test on the concentrated cells before freezing and the concentrated cells after freezing and thawing were 2.5 × 10 ¹¹ cfu / ml, and the freezing resistance of the concentrated cells was also good. there were.

  Therefore, it was found that the Lactococcus lactic acid bacteria of the present invention are suitable for industrial production.

Example 3 Lactis OLS3301 heat-killed bacterial colitis suppression test L. cerevisiae selected in Example 1 About the heat-killed microbial cell of lactis OLS3301, the colitis suppression test using the dextran sulfate sodium (DSS) induction mouse colitis model was done.

(1) Preparation of DSS-induced mouse colitis model and L. Administration of Lactis OLS3301 Heat-Deactivated Bacteria 21 BALB / c mice (female, 7 weeks old) were divided into 3 groups with 7 groups per group based on body weight. For the first group (also referred to as negative control group) and the second group (also referred to as 3% DSS control group), distilled water was 0.5 ml / body, and for the third group (also referred to as 3% DSS + OLS3301 group), Example 1 Prepared in L. lactis OLS3301 heat-killed cells 1 × 10 ⁹ cfu (0.5 ml distilled water) / body was orally administered once a day for 3 consecutive weeks. From the start of administration until 2 weeks later, drinking water was freely consumed in all groups. During the last week of the administration period (2 weeks after the start of administration to the end of the administration period), colitis was caused by setting the drinking water of groups 2 and 3 to 3% DSS. From 2 weeks after the start of administration to the end of the administration period, body weight was measured every day.

(2) Evaluation of colitis inhibitory effect The next day after the administration period was dissected, and the colitis inhibitory effect was evaluated. As an index for evaluation, the length of the large intestine (distal end of the cecum to anus) and DAI (disease activity index) were used. DAI is a method such as the Ottoman (Osman et al., Modulation of the Effect of Dextran Sulfate Sodium-induced Acte Colitis by the Administration of Different Probiotics Strains of Lactobacillus and Bifido-bacterium, Digestive Disease and Science, 2004 years, 49 (2) : 320-327). Specifically, the weight loss on the day of anatomy compared with the DSS administration start date, the presence or absence of loose stool and diarrhea on the day of anatomy, and bleeding from the anus were scored with the indices shown in Table 1, and the values obtained by summing these scores were obtained. DAI.

Since one individual in the second group was rejected by Smirnov (Smirnov) rejection test in the length of the large intestine, this individual was excluded from all the data thereafter.

(3) Results The results are shown in FIG. 2 and FIG. As shown in FIG. 2, significant intestinal shortening was observed in the 3% DSS control group as compared to the negative control group (P <0.01, student's t-test). In addition, L. In mice treated with lactis OLS3301 heat-killed cells (3% DSS + OLS3301 group), the shortening of the intestine accompanying the progression of colitis was significantly suppressed compared to mice in the group not administered (3% DSS control group). (P <0.01, student's t-test). In addition, as shown in FIG. 3, the 3% DSS + OLS3301 group showed a significant decrease in DAI compared to the 3% DSS control group (P <0.05, Mann Whitney U test). That is, L. The effect of suppressing colitis could be confirmed in lactis OLS3301 heat-killed cells.

[Example 4] Skin barrier function test It was tested whether or not the oral administration of lactis OLS3301 heat-killed microbial cells alleviated the damage of the skin barrier function caused by medium ultraviolet (UV-B) irradiation to mice. As an index of the skin barrier function, a transdermal water transpiration amount (TEWL (Trans Epidermal Water Loss)) that increases as the barrier function decreases is used.

(1) Preparation of dead cells by heating lactis OLS3301 strain was cultured in MRS broth at 30 ° C. for 30 hours. Bacteria were collected from the culture solution by centrifugation, washed twice with physiological saline, then once with distilled water, and heat-treated at 70 ° C. for 30 minutes to prepare heated dead cells. Then, it suspended in distilled water so that it might become 2 * 10 < ⁹ > cfu / ml, and preserve | saved at -20 degreeC.

(2) Animal test After acclimatization of 32 hairless mice (female, 7 weeks old, SLC) for 7 days, TEWL of the back skin was measured using a cyclone moisture transpiration monitor AS-CT1 (manufactured by Asahi Biomed). Each group was divided into 8 groups and 4 groups so that the TEWL values were the same. From the test start date (day-14), Group 1 and Group 2 were distilled water at 0.5 ml / body, Group 3 and Group 4 were 2 × 10 ⁹ cfu / ml of L. lactis OLS3301 heat-killed cells 0.5 ml / body was orally administered daily for 3 weeks. Two weeks after the start of administration, the water transpiration amount of each individual was measured, and then UV-B irradiation was performed once for groups 1 and 3 (day 0). UV-B irradiation is performed using a mouse equipped with three lamps (Philips TL 20W / 12RS, UV-B output: 2.1 (W) 5h, BLC Japan) having a dominant wavelength in the UV-B region. The animals were placed on the S cage and irradiated one by one in the cage. The irradiation amount of UVB was 1.5 kJ / m ² (irradiation with about 1.0 × 10 ⁻³ W / cm ² for 2.5 minutes). Furthermore, TEWL was measured after UVB irradiation. Thereafter, TEWL was measured once a day from 1 day after starting UV-B irradiation (day 1) to 7 days after (day 7).

(3) Results and discussion The results are shown in FIG. In the groups that were not irradiated with UV-B (groups 2 and 4), no increase in TEWL was observed. In the group irradiated with UV-B, distilled water administration group (Group 1), L.P. In the lactis OLS3301 heat-killed cell administration group (Group 3), TEWL increased peaking at 3 days after UV-B irradiation (day 3). However, L. In the group administered with lactis OLS3301 heated dead cells (group 3), the increase in TEWL was weak, and after 1 day of irradiation (day 1), after 5 days (day 5), after 6 days (day 6), after 7 days (day 7), distilled water was administered. Compared with (Group 1), it was significantly lower (P <0.05, Dunnett's test).

  From this, L. It has been found that lactis OLS3301 has the effect of suppressing or early recovery of TEWL increase, that is, a decrease in barrier function, which occurs after UV-B irradiation when taken orally. It has been found that the increase in TEWL by UV-B irradiation is associated with production of cytokines from T cells and hyperproliferation of epidermal cells (Reference 1: Haratake A., Uchida Y., Schmuth M., Tanno O., Yasuda R., Epstein JH., Elias PM., And Holleran WM., UVB-induced alterations in permeability of the symposium. ), Pp.769-775 (1997)), for suppressing inflammation in the skin Regulatory T cells are known to play an important role (Ref. 2: Dudda JC., Perdue N., Bachtianian E., and Campbell DJ., Foxp3 + regularity T cells main imine in the home. J. Exp. Med., 205 (7), pp. 1559-1565 (2008)). L. of the present invention. The oral administration of Lactis OLS3301 heat-killed cells induces regulatory T cells, suggesting the possibility of suppressing T cell activation and cytokine production.

  The Lactococcus lactic acid bacteria and / or processed product thereof, an immunoregulatory function inducer, or a food composition according to the present invention has an ability to induce large-scale production of IL-10, an anti-inflammatory cytokine, by immunocompetent cells. Moreover, with the ability to induce IL-10 production, induction of immune tolerance can be expected. In addition, since it is derived from fermented foods, it is safe and can be taken orally on a daily basis, and since it is easy to maintain quality in the case of dead cells, long-term administration such as inflammatory bowel disease is required. It is particularly effective for diseases.

Claims (10)

A Lactococcus lactic acid bacterium and / or a processed product thereof , which induces the production of interleukin-10 (IL-10) from immunocompetent cells in the intestine and enhances the immunoregulatory function, wherein the Lactococcus lactic acid bacterium is Lactococcus -The said Lactococcus genus lactic acid bacteria which are the lactis OLS3301 (Lactococcus lactis OLS3301; accession number NITE BP-432) strain | stump | stock, and / or its processed material .   The lactic acid bacterium of the genus Lactococcus and / or a processed product thereof according to claim 1, which is a Lactococcus lactis lactic acid bacterium. The Lactococcus lactic acid bacterium according to claim 1 or 2 , which is a dead cell, and / or a processed product thereof. An immunoregulatory function inducer comprising Lactococcus lactic acid bacteria and / or processed products thereof as an active ingredient, which induces the production of interleukin-10 (IL-10) from immunocompetent cells in the intestine and enhances the immunoregulatory function . The Lactococcus lactis OLS3301 (Lactococcus lactis OLS3301; accession number NITE BP-432) strain, the immunoregulatory function inducer . The immunoregulatory function inducer according to claim 4 , wherein the Lactococcus lactic acid bacterium is Lactococcus lactis lactic acid bacterium. 6. The immunoregulatory function inducer according to claim 4 or 5 , wherein the Lactococcus lactic acid bacterium is a dead cell. Induce the production of interleukin -10 (IL-10) from immunocompetent cells in the intestine, a Lactococcus and / or food composition comprising an effective amount of a processed product thereof to enhance the immunoregulatory function The above-mentioned food composition, wherein the Lactococcus lactic acid bacterium is Lactococcus lactis OLS3301 (Accession number NITE BP-432) strain . The food composition according to claim 7 , wherein the Lactococcus lactic acid bacterium is a Lactococcus lactis lactic acid bacterium. The food composition according to claim 7 or 8 , wherein the Lactococcus lactis lactic acid bacterium and / or a processed product thereof is a dead cell.   Lactococcus lactis OLS3301 (Accession number NITE BP-432) strain.

Images